Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 11,581 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $24.44, for a total transaction of $283,039.64. Following the completion of the sale, the chief financial officer now directly owns 118,077 shares of the company’s stock, valued at $2,885,801.88. The trade was a 8.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.98, for a total transaction of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total value of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98.

Hims & Hers Health Stock Up 1.1 %

Shares of NYSE HIMS opened at $26.19 on Wednesday. Hims & Hers Health, Inc. has a 52-week low of $8.14 and a 52-week high of $35.02. The stock has a market capitalization of $5.72 billion, a P/E ratio of 59.52 and a beta of 1.31. The stock’s 50 day moving average price is $27.42 and its two-hundred day moving average price is $21.72.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same period last year, the business posted ($0.04) earnings per share. The firm’s revenue for the quarter was up 77.1% on a year-over-year basis. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HIMS. GAMMA Investing LLC raised its stake in Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after acquiring an additional 2,152 shares during the period. Quest Partners LLC grew its holdings in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the last quarter. CWM LLC raised its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Quarry LP lifted its holdings in shares of Hims & Hers Health by 91.0% in the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after purchasing an additional 2,913 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their price objective for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Finally, Piper Sandler boosted their price target on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Monday, January 6th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.